RECRUITING

Transform CV Risk in Diabetes

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to cardiometabolic team-based care model, and general educational tools/resources) to im-prove use of guideline-directed therapeutics known to lower cardiovascular risk (CV) in patients with type 2 diabetes (T2D).

Official Title

Transform CV Risk in Diabetes

Quick Facts

Study Start:2023-09-01
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05948969

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * T2D diagnosis in the medical record
  2. * ASCVD, defined as follows:
  3. 1. Known Coronary artery disease (CAD), prior Acute coronary syndrome (ACS), or coronary artery revascularization
  4. 2. Prior TIA/ischemic stroke or known carotid or intracerebral atherosclerosis, or prior carotid revascularization
  5. 3. Prior Peripheral artery disease (PAD) including symptomatic claudication or pe-ripheral revascularization
  1. * Current participation in an interventional clinical assessment of an investigational drug/device (excluding assessments related to COVID-19)
  2. * Currently receiving any SGLT2i or GLP-1RA
  3. * Known allergy/hypersensitivity/intolerance/contraindication to SGLT2i or GLP-1RA
  4. * Currently receiving comfort care or enrolled in hospice
  5. * Life expectancy \<1 year
  6. * History of or plan for heart transplantation or ventricular assist device
  7. * Current or planned hemodialysis
  8. * Decompensated end stage liver disease
  9. * History of Fournier's Gangrene
  10. * Type 1 diabetes
  11. * Prior history of diabetic ketoacidosis
  12. * Pregnancy or active breastfeeding
  13. * History of Pancreatitis or pancreatic cancer
  14. * History of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2)

Contacts and Locations

Study Contact

Shilpa Patel
CONTACT
2023756354
SPatel@acc.org
Jack Reilly
CONTACT
202
JReilly@acc.org

Study Locations (Sites)

Multiple sites nationwide
Washington, District of Columbia, 20004
United States

Collaborators and Investigators

Sponsor: American College of Cardiology

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-01
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2023-09-01
Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Type 2 Diabetes